Vomiting is one of the most distressing adverse effects of cancer chemotherapy. Metoclopramide by continuous infusion (400 μg/kg/h after a loading dose of 2.5 mg/kg) is a novel administration method for optimizing efficacy. A two-year-old boy developed urinary retention on three occasions, once accompanied by priapism and slurred speech, while receiving a continuous infusion. This was reversed by procyclidine, suggesting that it may have been a dystonic reaction.
Get full access to this article
View all access options for this article.
References
1.
SallerRHellenbrechtDBriemanLMetoclopramide kinetics at high-dose infusion rates for the prevention of cisplatin-induced emesis. Clin Pharmacol Ther1985; 37: 43–7.
2.
JossRAGaleazziRLBrunnerKW. Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. Eur J Clin Pharmacol1983; 25: 35–9.
3.
TaylorWBSimpsonJMBatemanDN. High dose metoclopramide by infusion. A double blind study of plasma concentration effect relationships in patients receiving cancer chemotherapy. Eur J Clin Pharmacol1987; 33: 161–5.
4.
GrallaRJLitriLMPiscoSEAntiemetic efficacy of high dose metoclopramide: Randomized trial with placebo and prochlorperazine in patients with chemotherapy induced nausea and vomiting. N Engl J Med1981; 305: 905–9.
5.
WarringtonPSAllanSGCornbleetMAOptimising antiemesis in cancer chemotherapy: Efficacy of continuous versus intermittent infusion of high-dose metoclopramide in emesis induced by cisplatin. Br Med J1986; 293: 1334–7.
6.
DanaBWMcDermottMEvertsEA randomized trial of high dose bolus metoclopramide versus low dose continuous infusion metoclopramide in the prevention of cisplatin-induced emesis. Am J Clin Oncol1987; 10: 253–6.
7.
DesmondPVWatsonKJR. Metoclopramide—a review. Med J Aust1986; 144: 366–9.
8.
MitchellWCVenablesDD. Effects of metoclopramide on detrusor function. J Urol1985; 134: 791–4.
9.
KumarBB. Urinary incontinence associated with metoclopramide (letter). JAMA1984; 251: 155.
10.
FozardJR. Neuronal 5-HT receptors in the periphery. Neuropharmacology1984; 23: 1473–86.
11.
MinerWDSangerGJ. Inhibition of cisplatin induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol1986; 88: 497–9.
12.
CostallBDomeneyAMNaylorRJ5-hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology1986; 25: 959–61.
13.
BatemanDNCraftAWNicholsonEPearsonADJ. Dystonic reactions and the pharmacokinetics of metoclopramide in children. Br J Clin Pharmacol1983; 15: 557–9.
14.
WhitemanPDFowleASEHamiltonMJPharmacokinetics and pharmacodynamics of procyclidine in man. Eur J Clin Pharm1985; 28: 73–8.
15.
VaidyanathanSRaoMSBapnaBCCharyKSNSwamyRP. Role of dopamine receptors in vesicourethral function. Ann Clin Res1980; 12: 1–4.
16.
5HT receptor antagonists: A new class of antiemetics (editorial). Lancet1987; 1: 1470–1.
